Compounders Research Compare

MoonLake Immunotherapeutics(MLTX)

Biotechnology · Zug, ZG

$11.00-0.38 (-3.34%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Zug, ZG

130 employees

www.moonlaketx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jorge Santos da Silva

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T18:03:47.691Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:03:47.691Z.

Quote observation: 2026-10-06T18:00:24.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 925,269,400
TTM free cash flow · period ending 2026-06-30: -225,181,000

FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

MLTX Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

MLTX Competitors' Price/FCF Ratio

MoonLake Immunotherapeutics

Current

Market Cap

$925.27M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CeriBell, Inc.

Market Cap

$930.12M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HealthStream, Inc.

Market Cap

$913.71M

Price/FCF Ratio

18.71

TTM Avg

13.52

3Y Avg

15.51

5Y Avg

16.87

Kura Oncology, Inc.

Market Cap

$938.44M

Price/FCF Ratio

N/A

TTM Avg

6.84

3Y Avg

6.83

5Y Avg

6.83

Odyssey Therapeutics, Inc.

Market Cap

$901.55M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Seaport Therapeutics, Inc. Common Stock

Market Cap

$946.27M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bioventus Inc.

Market Cap

$899.69M

Price/FCF Ratio

9.54

TTM Avg

9.57

3Y Avg

34.87

5Y Avg

48.37

Savara Inc.

Market Cap

$950.86M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aktis Oncology, Inc.

Market Cap

$966.09M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Arbutus Biopharma Corp

Market Cap

$877.52M

Price/FCF Ratio

N/A

TTM Avg

27.25

3Y Avg

19.97

5Y Avg

19.97

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
MoonLake Immunotherapeutics (MLTX)	$925.27M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$930.12M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$913.71M	18.71	13.52	15.51	16.87
Kura Oncology, Inc. (KURA)vs ›	$938.44M	N/A	6.84	6.83	6.83
Odyssey Therapeutics, Inc. (ODTX)vs ›	$901.55M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$946.27M	N/A	N/A	N/A	N/A
Bioventus Inc. (BVS)vs ›	$899.69M	9.54	9.57	34.87	48.37
Savara Inc. (SVRA)vs ›	$950.86M	N/A	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$966.09M	N/A	N/A	N/A	N/A
Arbutus Biopharma Corp (ABUS)vs ›	$877.52M	N/A	27.25	19.97	19.97

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics